Corporate News

Medicilon’s Antibody peptide conjugates service platform
ACEA Pharma’s Ogrelvir Sodium Capsule Named in Nature’s 2025 Top Novel Target Drugs List with R&D Support from Medicilon
Medicilon Supports Partner Nanolattix, Two RDC and ADC Studies Accepted for EANM’26; HER2/TF Bispecific Research Selected as Top-Rated Oral Presentation
Powering Another GLP‑1/GIP Dual Receptor Agonist for Global Expansion! Medicilon Congratulates Hengrui Pharma on Exclusive License Agreement with Novo Nordisk for HRS‑1596
Medicilon Congratulates : MindRank AI-Developed Oral GLP-1 MDR-001 Secures Up to RMB 1.75 Billion Exclusive Commercialization Deal with Sunshine Mandi
A Note of Appreciation, A Mark of Recognition | Medicilon Supports Partner Tasly in Obtaining Clinical Trial Approval for TSL2402 Tablets

Events

Oct. 15 (Thu.) - 16 (Fri.), 2026. Venue, Alpensia Resort, Pyeongchang, South Korea.
50th Korean Society of Nonclinical Studies (KSNS)
Oct. 7 (Wed.) - 9 (Fri.), 2026 10:00-17:00. Venue, PACIFICO Yokohama.
BIOJAPAN 2026
Basel, Switzerland from September 6-10, 2026
EFMC-ISMC 2026
Date: August 27-28, 2026
Venue:The Westin Seoul Parnas, South Korea - Medicilon Booth #6
4th SMC and AimedBio ADC Conference
Date: August 23-27, 2026
Venue: McCormick Place Convention Center, Chicago, IL - Medicilon Booth #400
ACS Fall 2026
Date: September 10, 2026 (Thursday)
Venue: EL Tower, Ruby Hall, Yangjae, Seoul
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026

Medicilon Academy

【Case Study】New Approach Methods NAMs
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Boston Non-Tumor Models Innovation
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology

Digital Materials

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK
A Sensitive LC–MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level (Download)
Quantification of antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform (Download)
Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)

Search Medicilon

Preclinical CRO

Medicilon’s Antibody peptide conjugates service platform

Preclinical CRO

ACEA Pharma’s Ogrelvir Sodium Capsule Named in Nature’s 2025 Top Novel Target Drugs List with R&D Support from Medicilon

Preclinical CRO

Medicilon Supports Partner Nanolattix, Two RDC and ADC Studies Accepted for EANM’26; HER2/TF Bispecific Research Selected as Top-Rated Oral Presentation

Contact Medicilon

Name(Required)
Address(Required)